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otherwise. A correct analysis of data on cardiac valvular 
prostheses allows a better understanding of the results of 
such procedures and enables surgeons to choose the 
appropriate prostheses for their patients. 
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Tracheal sleeve pneumonectomy for bronchogenic 
carcinoma 
To the Editor: 
The January 1994 issue of this JOURNAL included our 
article, titled "Tracheal Sleeve Pneumonectomy forBron- 
chogenic Carcinoma" (J THORAC CARDIOVASC SURG 94; 
107:13-8). The work reported our experience with 28 
tracheal sleeve pneumonectomies (TSPs), 27 right TSPs 
and one left TSP. The very low operative mortality (only 
one death, which occurred on the thirtieth postoperative 
day as a result of myocardial infarction) and the absence 
of anastomotic complications (stenosis and dehiscence) 
seemed to impress the readers, as indicated by the many 
reprint reque.sts and letters with specific questions on 
technical details of tracheobronchial anastomosis, on an- 
esthesia modalities, and on preoperative and postopera- 
tive care. 
High mortality rates are commonly reported in the 
literature (8% to 29%). The progress of ventilation tech- 
niques and of suture-performing modalities have allowed 
acceptanc e of TSP. Nevertheless, TSP is still carried out 
only in centers highly qualified to perform thoracic sur- 
gery. 
From 1992 (when the period of observation ended) to 
date we have performed seven more right TSPs on 
patients with lung cancer involving the tracheobronchial 
angle. In this last group of patients we recorded two 
deaths caused by postoperative complications which, in 
our opinion, were due to inappropriate preoperative 
radiotherapy. In this letter we would like to stress the 
negative effects of high-dose radiotherapy in patients 
eligible for TSP. 
Like other authors, we adopted preoperative radiation 
treatment to reduce the tumor size, so as to facilitate the 
anastomotic procedure. We chose the low-dose protocol 
introduced by Paulson and associates, 1 reserving it for 
large neoplasms that might be expected to benefit most 
from combined radiotherapeutic and surgical treatment. 
No radiotherapy is planned in small tumors. 
In our series, of 35 patients subjected to TSP, 14 
received a preoperative radiotherapy protocol consisting 
of 10 treatments of 30 Gy each. One patient had preop- 
erative chemotherapy. Another patient had both radio- 
therapy and chemotherapy. Seventeen patients did not 
receive any preoperative treatment. Two patients had 
high-dose radiotherapy (60 Gy). Their clinical history and 
the reasons for the high-dose radiation treatment, which 
in our opinion caused the patients' deaths, are briefly 
described. 
The first patient, a 67-year-old man, was counselled to 
receive radiotherapy in 30 Gy doses. We were unaware 
that his son, who is a physician, decided to subject the 
patient to 60 Gy doses. Evaluation after radiotherapy 
showed a good result and the patient was therefore 
subjected to TSP. The postoperative course was normal 
until the ninth postoperative day, when clinical and roent- 
genographic signs of bronchial fistula developed. A bron- 
choscopic examination showed a hyperemic anastomosis 
covered with fibrin and without any sign of tissue healing: 
the endoscopic picture closely resembled that of the 
immediate postoperative p riod. A small bronchial fistula 
was found on the right edge of the suture. A tracheostomy 
was done and the patient was intubated with the same 
tube (Sybilla's tube) that we used to carry out the anas- 
tomosis, by inflating the balloon distal to the anastomosis. 
The pleural cavity was drained. The patient had a number 
of complications, and he died on postoperative day 22 of 
a fatal hemorrhage from a gastric ulcer. Repeated bron- 
choscopic studies during the course had all failed to show 
granulation tissue or other signs of healing on the anas- 
tomosis. 
The second patient was a 71-year-old man. Despite our 
prescription for preoperative radiation therapy in 30 Gy 
doses, his condition was judged inoperable by the radio- 
therapist who therefore subjected him to 60 Gy doses. 
This treatment yielded a remarkable reduction of the 
mass. Because we were not sure of the actual responsibil- 
ity of excessive preoperative radiation in determining 
bronchial dehiscence in the previous case, and considering 
the good general conditions of this patient, we decided to 
perform TSP. 
On the first postoperative day a conspicuous bronchor- 
rhea developed that necessitated repeated bronchial suc- 
tions. The patient died on the eighth postoperative day of 
pulmonary edema. A bronchoscopic examination had 
revealed a normal tracheobronchial anastomosis. 
Jensik and coworkers, 2 in an article published in 1982, 
had already stressed the fact that postoperative mortality 
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was significantly greater in patients preoperatively treated 
with 5000 rad. In our global experience, no technical or 
clinical problems occurred in patients subjected to a 
preoperative dose of 30 Gy. After these last two failures, 
whenever reduction of the tumor size is needed to facili- 
tate the procedure, we recommend that a preoperative 
radiation dose of no greater than 30 Gy be used. 
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Topical use of aprotinin in cardiac surgery 
To the Editor: 
We read with great interest he letters concerning the 
topical effect of aprotinin by Edmunds 1 and by Tabuchi, 
de Haan, and van Oeveren. a 
We 3 demonstrated the efficacy of topical aprotinin (1 
million KIU) in the pericardial cavity in reducing postop- 
erative blood loss in patients undergoing cardiac opera- 
tions. 30 'Regan and associates 4 recently reported that 
topical application of aprotinin in the pericardial cavity 
significantly reduced the postoperative blood loss after 
cardiac operations. The mechanism by which aprotinin 
exerts its effect topically differs from its systemic effect, 
wherein the mechanism of action is conservation ofplate- 
let function and inhibition of fibrinolysis. 
de Haan and associates 5 reported an increased activity 
of tissue-plasminogen activator from the pericardium and 
proposed a fibrinolysis-related bleeding tendency after 
cardiopulmonary b pass. Of equal interest is a recent 
report by Tabuchi and associates, 6 who demonstrated 
enormous activation of fibrinolysis on the surgical wound 
during cardiopulmonary b pass. Tabuchi, de Haan, and 
van Oeveren 2 have recently reported a tremendous in- 
crease of fibrin degradation products in the blood of the 
surgical wound compared with systemic blood. Low-dose 
systemic aprotinin reduced fibrin degradation products in 
wound blood by half compared with that in a control 
group (17,900 -+ 6,800 ng/ml versus 38,200 ___ 9,300 ng/ml). 
The results of these studies, 2'5' 6 combined with the 
results of Tatar, 3 and O'Regan, 4 and their colleagues, 
suggest that a local fibrinolytic state persists after closure 
of the thoracic avity and contributes to the postoperative 
blood loss. Topical aprotinin seems to exert an antifibrino- 
lyric action by which it stabilizes fibrin sealing of the 
surgical wound. 
Systemic absorption and effect of the topically applied 
aprotinin is a concern. The plasma aprotinin levels were 
measured in eight patients in our original study, and 
aprotinin could not be detected in any. However, this was 
a small number from which to reach a conclusion. There- 
fore we measured systemic drug concentrations in 30 of 
150 patients in whom we used aprotinin topically (1 
million KIU) in the pericardial cavity immediately after 
our original study at the GATA Department of Cardio- 
vascular Surgery. Systemic aprotinin levels were deter- 
mined by means of the sandwich-enzyme-linked immu- 
nosorbent assay technique at the first hour after the chest 
tubes were unclamped. Aprotinin could not be detected in 
any patient's blood. The exposure time to topical aproti- 
nin was 11.4 minutes on average. Although aprotinin is a 
small molecule (about 7000 daltons), short exposure time 
and low topical dose limit systemic absorption. Our data 
once again confirm that the drug remains restricted to the 
pericardial space and the effect is completely due to 
topical action. 
Although aprotinin has been reported as safe in earlier 
studies, a number of adverse reactions including renal 
impairment, graft occlusion, anaphylaxis after reuse, and 
disseminated intravascular coagulation after profound 
hypothermic bypass have begun to accumulate with in- 
creasing systemic use of aprotinin. The topical use of 
aprotinin will completely abolish most of the complica- 
tions and eliminate the need for prophylactic use. We 
have used topical aprotinin extensively since 1991 with no 
adverse actions or intolerance. Another important consid- 
eration is treatment cost, which may be reduced by 
approximately 80% with the topical use of the drug. 
We agree that "nothing is ever simple in the enzymatic 
stew of coagulation ''1 but believe that a simple approach 
to the problems ometimes brings better solutions. In our 
opinion, topical use of aprotinin will be established as a 
therapeutic option to reduce postoperative blood loss. It 
can at least be combined with systemic use to reduce the 
high intravenous doses. We also emphasize that careful 
surgical hemostasis i the key in reducing postoperative 
blood loss and that pharmacologic agents hould be used 
not as an alternative but a supplement to surgical hemo- 
stasis. 
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